For seven years he believed a blood cancer would eventually kill him. Then a nurse at a routine appointment raised a concern.

Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need ...

Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course. During a ...

Silence Therapeutics plc (NASDAQ:SLN) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead ...

Rusfertide showed a 77% clinical response rate in polycythemia vera patients, significantly higher than the 33% with placebo. The drug reduced phlebotomy frequency, with 0.5 per patient in the ...

Nuvisertib received FDA fast track designation for myelofibrosis, showing significant clinical activity in symptom and spleen response, and improvements in bone marrow fibrosis, hemoglobin, and ...

Silence Therapeutics Plc SLN stock rose Wednesday after Cantor Fitzgerald initiated coverage with an Overweight rating and a ...

Please provide your email address to receive an email when new articles are posted on . The data was reviewed at the 14th International Congress on Myeloproliferative Neoplasms. “These patients that ...

Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

This viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and ...

VIENNA--(BUSINESS WIRE)--AOP Orphan Pharmaceuticals GmbH (AOP Health) announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with ...

During the past 35 years, single-arm studies documented the efficacy and safety of recombinant interferon alpha (rIFNα) for treating polycythemia vera (PV). In some patients, 2-5 years of ...